All In Biotech

Drug Trial Radar · NCT07723469

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

A Randomized, Phase 3 Trial of SRG-514 Administered Intraoperatively to the Site of Tumor Resection in Patients Undergoing Breast-Conserving Surgery for Triple Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Oct 2034

Study completion Oct 2034

Sponsor

Lead sponsor
SURGE TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.

Conditions

  • TNBC - Triple-Negative Breast Cancer

Interventions

  • BCS + SRG-514Drug

    BCS + SRG-514

  • BCSProcedure

    BCS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EFS by BICR assessmentTime frame: EFS is defined as the time from randomization to the first occurrence of an event up to 5 years post BCS.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo

    Rochester, Minnesota

  • NYU Langone Health

    New York, New York

  • Duke Cancer Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.